Suchergebnisse - "Klausmann, Martine"

PubPharm (3)

1

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7) : part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

enthalten in: The Lancet. Haematology | 2022

von Goldschmidt, H. | Mai, E. | Bertsch, U. | +123

CommentIn: Lancet Haematol. 2022 Nov;9(11):e798-e799. - PMID 36328036

2

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1) : an open-label, multicentre, randomised, phase 3 trial

enthalten in: The Lancet. Haematology | 2022

von Dimopoulos, M. | Richardson, P. | Bahlis, N. | +124

CommentIn: Lancet Haematol. 2022 Jun;9(6):e386-e387. - PMID 35550059

3

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

enthalten in: The New England journal of medicine | 2019

von Facon, T. | Kumar, S. | Plesner, T. | +128

CommentIn: N Engl J Med. 2019 May 30;380(22):2172-2173. - PMID 31141641

1
[1]